オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - baricitinib, quantity: 4 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; mannitol; microcrystalline cellulose; polyvinyl alcohol; titanium dioxide; macrogol 3350; purified talc; lecithin; iron oxide red - rheumatoid arthritis,olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately, or who are intolerant, to one or more dmards.,olumiant can be taken as monotherapy or in combination with cdmards, including methotrexate (mtx).,atopic dermatitis,olumiant is indicated for the treatment of moderate to severe atopic dermatitis (ad) in adult patients who are candidates for systemic therapy.,alopecia areata,olumiant is indicated for the treatment of severe alopecia areata (aa) in adult patients in whom other treatments have failed or are not appropriate and no spontaneous improvement is observed (see section 5.1 pharmacodynamic properties; clinical trials).

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - baricitinib, quantity: 2 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; mannitol; microcrystalline cellulose; polyvinyl alcohol; titanium dioxide; macrogol 3350; purified talc; lecithin; iron oxide red - rheumatoid arthritis,olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately, or who are intolerant, to one or more dmards.,olumiant can be taken as monotherapy or in combination with cdmards, including methotrexate (mtx).,atopic dermatitis,olumiant is indicated for the treatment of moderate to severe atopic dermatitis (ad) in adult patients who are candidates for systemic therapy.,alopecia areata,olumiant is indicated for the treatment of severe alopecia areata (aa) in adult patients in whom other treatments have failed or are not appropriate and no spontaneous improvement is observed (see section 5.1 pharmacodynamic properties; clinical trials).

マルタ - 英語 - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - mianserin hydrochloride - film-coated tablet - mianserin hydrochloride 10 mg - psychoanaleptics

マルタ - 英語 - Medicines Authority

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - mianserin hydrochloride - film-coated tablet - mianserin hydrochloride 10 mg - psychoanaleptics

マルタ - 英語 - Medicines Authority

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - mianserin hydrochloride - film-coated tablet - mianserin hydrochloride 30 mg - psychoanaleptics

マルタ - 英語 - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - mianserin hydrochloride - film-coated tablet - mianserin hydrochloride 30 mg - psychoanaleptics

マルタ - 英語 - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - mianserin hydrochloride - film-coated tablet - mianserin hydrochloride 30 mg - psychoanaleptics

マルタ - 英語 - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - mianserin hydrochloride - film-coated tablet - mianserin hydrochloride 10 mg - psychoanaleptics

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

generics (uk) limited - mianserin hydrochloride - film coated tablet - 30 milligram

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

generics (uk) limited - mianserin hydrochloride - film coated tablet - 10 milligram